Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 May 2020

Petelin Lara, Hossack Lucinda, Shanahan Mary, Mitchell Gillian, Liew Danny, James Paul A, Trainer Alison H

Abstract excerpt

PURPOSE: Women who inherit a BRCA1 or BRCA2 pathogenic variant are at high risk of developing breast and ovarian cancer. Evidence for the effectiveness and cost-effectiveness of long-term management in clinical practice is lacking. The purpose of this study was to evaluate the real-world cost-effectiveness of BRCA carrier management within a structured clinical program. METHODS: Lifetime health outcomes and costs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mastectomy

Share to Mutation

Share to Ovarian Neoplasms

Share to Ovariectomy

Share to Quality-Adjusted Life Years

Share to Young Adult

Source

Identifiers

PMID: 31996782
DOI: 10.1038/s41436-020-0751-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.PMID 31996782Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

A cost analysis of a cancer genetic service model in the UKSemantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.Semantic proximity Read ↗

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Semantic proximity Read ↗

A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.